Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$164.99 USD

164.99
4,422,792

-2.37 (-1.42%)

Updated Sep 5, 2024 04:00 PM ET

After-Market: $164.96 -0.03 (-0.02%) 5:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Mark Vickery headshot

Retail Sales Hotter at +0.7%; JNJ, BAC, GS All Beat in Q3

Retail Sales infer a consumer willing to spend, and the outlook for Q3 GDP is likely up somewhat on this news.

Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Johnson & Johnson (JNJ) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Johnson & Johnson (JNJ) Q3 Earnings and Revenues Surpass Estimates

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 5.56% and 1.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Markets Pop on Bargain Hunting, Stronger Economy

The small-cap Russell 2000, still under water over the past month, led the way higher today.

John Blank headshot

Will Big Stocks Make Big Headlines? Global Week Ahead

This trading week might offer some reassurance -- that both households and businesses are holding up -- in an uncertain macro environment.

Wall Street Waits for Big Earnings Results

Wall Street Waits for Big Earnings Results.

Mark Vickery headshot

Empire State Less Bad than Expected; SCHW Mixed in Q3

We've only seen four months in positive territory on Empire State manufacturing year to date, the highest being +10.8 in April.

Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?

Smart Beta ETF report for DGRO

Eli Lilly's (LLY) Mirikizumab Meets Crohn's Disease Study Goals

Based on this data, Eli Lilly (LLY) will initiate regulatory submissions worldwide next year seeking regulatory approval for mirikizumab in Crohn's disease.

J&J (JNJ) to Report Q3 Earnings, Its First After Unit Spin-Off

J&J's (JNJ) third-quarter results are the first quarterly update for the new company after the Consumer Health spin-off.

Kinjel Shah headshot

Pharma Stock Roundup: LLY Meets IBD Study Goal, PFE, MRK Give Cancer Pipeline Updates

Eli Lilly's (LLY) mirikizumab meets the main goals in a Crohn's disease study. PFE, MRK and JNJ provide updates on cancer drugs in their pipeline.

Sweta Killa headshot

Dow ETF in Focus Ahead of Q3 Earnings

With some of the blue-chip companies having reasonable chances of coming up with an earnings surprise, investors should closely monitor the movement of the Dow ETF and grab any opportunity that arises from a surge in any of the 30 stocks.

Earnings Preview: Johnson & Johnson (JNJ) Q3 Earnings Expected to Decline

Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?

Style Box ETF report for HDV

Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?

Smart Beta ETF report for VYM

J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC

J&J (JNJ) files an application in Europe seeking expanded approval for Rybrevant as a first-line combination treatment in patients with advanced or metastatic EGFR exon 20 insertion mutation-positive NSCLC.

Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Sanofi (SNY) Inks Deal With J&J to Develop E. coli Vaccine

Per the terms of the deal, Sanofi (SNY) and J&J will co-fund current and future R&D costs to develop a potential first-in-class vaccine against extraintestinal pathogenic E. coli.

Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know

Johnson & Johnson (JNJ) closed at $155.15 in the latest trading session, marking a -0.39% move from the prior day.

J&J's (JNJ) Rybrevant Combo Meets Primary Goal in NSCLC Study

J&J (JNJ) meets the primary goal in the late-stage study of the combination therapy of Rybrevant and lazertinib against Tagrisso for EGFR-mutated first-line NSCLC.

The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J

AbbVie, Lilly, Sanofi, Merck and J&J are included in this Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs

The European Commission approves AbbVie's (ABBV) Tepkinly (epcoritamab) for DLBCL. FDA approves Lilly's (LLY) Jardiance for chronic kidney disease.